GRAIL, Inc. Common Stock
GRAL Real Time Price USDRecent trades of GRAL by members of U.S. Congress
---
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in GRAL holdings by institutional investors
Quarterly net insider trading by GRAL's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More about Alpha -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More about Annual Standard Deviation -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More about Annual Volatility -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More about Beta -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More about CAGR -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More about Information Ratio -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More about Max Drawdown -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More about Sharpe Ratio -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More about Treynor Ratio -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$10,000 Oct 14, 2026 Issue: Health Issues
-
$50,000 Jul 20, 2026 Issue: Health Issues Medicare/Medicaid
-
$20,000 Jul 20, 2026 Issue: Health Issues Medicare/Medicaid
-
$50,000 Jul 20, 2026 Issue: Medicare/Medicaid
-
$30,000 Jul 20, 2026 Issue: Health Issues
-
$50,000 Jul 20, 2026 Issue: Medicare/Medicaid
-
$790,000 Jul 20, 2026 Issue: Health Issues Medicare/Medicaid
-
$10,000 Jul 10, 2026 Issue: Health Issues
-
$60,000 Jul 09, 2026 Issue: Medicare/Medicaid
-
$610,000 Apr 20, 2026 Issue: Health Issues Medicare/Medicaid
-
$50,000 Apr 20, 2026 Issue: Medicare/Medicaid Health Issues
-
$50,000 Apr 20, 2026 Issue: Medicare/Medicaid
-
$20,000 Apr 20, 2026 Issue: Health Issues Medicare/Medicaid
-
$50,000 Apr 18, 2026 Issue: Health Issues Medicare/Medicaid
-
$60,000 Apr 17, 2026 Issue: Medicare/Medicaid
-
$30,000 Apr 14, 2026 Issue: Health Issues
-
$30,000 Apr 09, 2026 Issue: Health Issues Medicare/Medicaid
-
$20,000 Jan 20, 2026 Issue: Health Issues Medicare/Medicaid
-
$30,000 Jan 20, 2026 Issue: Health Issues Medicare/Medicaid
-
$50,000 Jan 20, 2026 Issue: Medicare/Medicaid Health Issues
-
$50,000 Jan 20, 2026 Issue: Medicare/Medicaid
-
$20,000 Jan 20, 2026 Issue: Health Issues Medicare/Medicaid
-
$470,000 Jan 20, 2026 Issue: Medicare/Medicaid Health Issues
-
$50,000 Jan 18, 2026 Issue: Health Issues Medicare/Medicaid
-
$60,000 Jan 16, 2026 Issue: Medicare/Medicaid
-
$30,000 Jan 15, 2026 Issue: Health Issues
-
$50,000 Oct 20, 2025 Issue: Health Issues Medicare/Medicaid
-
$20,000 Oct 20, 2025 Issue: Health Issues Medicare/Medicaid
-
$600,000 Oct 20, 2025 Issue: Medicare/Medicaid Health Issues
-
$60,000 Oct 20, 2025 Issue: Medicare/Medicaid
-
$50,000 Oct 20, 2025 Issue: Medicare/Medicaid
-
$20,000 Oct 20, 2025 Issue: Health Issues Medicare/Medicaid
-
$50,000 Oct 19, 2025 Issue: Health Issues Medicare/Medicaid
-
$30,000 Oct 18, 2025 Issue: Health Issues Medicare/Medicaid
-
$30,000 Oct 09, 2025 Issue: Health Issues
-
$20,000 Jul 21, 2025 Issue: Health Issues Medicare/Medicaid
-
$580,000 Jul 21, 2025 Issue: Health Issues Medicare/Medicaid
-
$50,000 Jul 21, 2025 Issue: Medicare/Medicaid Health Issues
-
$50,000 Jul 21, 2025 Issue: Medicare/Medicaid
-
$30,000 Jul 21, 2025 Issue: Health Issues Medicare/Medicaid
-
$20,000 Jul 21, 2025 Issue: Health Issues Medicare/Medicaid
-
$60,000 Jul 21, 2025 Issue: Medicare/Medicaid
-
$50,000 Jul 18, 2025 Issue: Health Issues Medicare/Medicaid
-
$30,000 Jul 15, 2025 Issue: Health Issues
-
$500,000 May 05, 2025 Issue: Health Issues Medicare/Medicaid
-
$50,000 Apr 21, 2025 Issue: Medicare/Medicaid
-
$50,000 Apr 21, 2025 Issue: Medicare/Medicaid Health Issues
-
$20,000 Apr 21, 2025 Issue: Health Issues Medicare/Medicaid
-
$20,000 Apr 21, 2025 Issue: Health Issues Medicare/Medicaid
-
$20,000 Apr 21, 2025 Issue: Medicare/Medicaid
-
$30,000 Apr 20, 2025 Issue: Health Issues Medicare/Medicaid
-
$30,000 Apr 17, 2025 Issue: Health Issues
-
$50,000 Apr 15, 2025 Issue: Health Issues Medicare/Medicaid
-
$30,000 Jan 21, 2025 Issue: Health Issues Medicare/Medicaid
-
$20,000 Jan 21, 2025 Issue: Health Issues Medicare/Medicaid
-
$50,000 Jan 21, 2025 Issue: Medicare/Medicaid
-
$650,000 Jan 21, 2025 Issue: Health Issues Medicare/Medicaid
-
$50,000 Jan 21, 2025 Issue: Health Issues Medicare/Medicaid
-
$50,000 Jan 21, 2025 Issue: Medicare/Medicaid
-
$30,000 Jan 20, 2025 Issue: Health Issues
-
$50,000 Jan 17, 2025 Issue: Health Issues Medicare/Medicaid
-
$30,000 Oct 21, 2024 Issue: Medicare/Medicaid Health Issues
-
$50,000 Oct 21, 2024 Issue: Medicare/Medicaid
-
$540,000 Oct 21, 2024 Issue: Medicare/Medicaid Health Issues
-
$50,000 Oct 21, 2024 Issue: Medicare/Medicaid
-
$50,000 Oct 21, 2024 Issue: Medicare/Medicaid Health Issues
-
$30,000 Oct 21, 2024 Issue: Medicare/Medicaid Health Issues
-
$30,000 Oct 18, 2024 Issue: Health Issues
-
$50,000 Oct 17, 2024 Issue: Medicare/Medicaid Health Issues
-
$30,000 Jul 22, 2024 Issue: Medicare/Medicaid Health Issues
-
$50,000 Jul 22, 2024 Issue: Medicare/Medicaid
-
$30,000 Jul 22, 2024 Issue: Medicare/Medicaid Health Issues
-
$50,000 Jul 22, 2024 Issue: Medicare/Medicaid Health Issues
Former government officials who have lobbied for GRAL
42 former government officials from 28 congressional offices at 14 lobbying firms have lobbied for GRAL, most recently Jul 20, 2026.
-
Jeanne Haggerty Senate Legislative Correspondent Senator Chuck Grassley and Senate Aging Committee (shared staff), Legislative Aide Senate Finance Committee, Health Policy Coordinator Health Subcommittee Energy and Commerce, Professional Staff Member -
Robert Butora Senate Health Policy Advisor, Senator Bill Cassidy; Senior Health Policy Advisor, Representative Leonard Lance, Health Legislative Assistant, Representative Michael Burgess -
James Hall Senate Staff Director, Senate Veterans Affairs Committee; Legislative Director, Senator Bob Graham
-
Hazen Marshall Senate Policy Director-Senate Majority Leader Mitch McConnell; Staff Director, Senate Budget Committee-Senator Don Nickles; Deputy Chief of Staff/Economist, Office of Assistant Majority Leader-Senator Don Nickles; Legislative Assistant-Senator Don Nickles -
Monica Popp Senate Chief of Staff/Deputy Chief of Staff, Office of Senate Republican Whip John Cornyn; Professional Staff Member, U.S. House of Representatives-Energy & Commerce Committee; Legislative Assistant, Senator Jim DeMint -
Natalie Mcintyre Congress New Special Assistant to the President, Office of Legislative Affairs; Sen. Bill Hagerty Legislative Director; OMB Deputy Associate Director, Legislative Affairs; ONDCP Senior Policy Advisor and White House Liaison; Sen. McConnell Legislative Assistant
-
Barbara Menard Senate New Senior Executive Service-ARPA-H/HHS (Jan 2023-Apr 2025) Senior Executive Service-OMB/Executive Office of the President (Oct 2013-Jan 2023) Deputy Chief of Staff, Sen. Chris Dodd (Sept 2008-July 2010) -
Ashley Gunn House Special Asst to the President, Senior Director, White House Office of Cabinet Affairs.
GRAL Estimated quarterly lobbying spending
GRAL Revenue by Segment or Geography
New GRAL patent grants
-
Patent Title: Method and system of cancer detection using cpg-snp contamination markers Jul. 21, 2026
-
Patent Title: Systems and methods for cancer condition determination using autoencoders Jun. 02, 2026
-
Patent Title: Method and system for selecting, managing, and analyzing data of high dimensionality May. 12, 2026
-
Patent Title: Identifying methylation patterns that discriminate or indicate a cancer condition Mar. 17, 2026
-
Patent Title: Methods of preparing dual-indexed dna libraries for bisulfite conversion sequencing Dec. 30, 2025
-
Patent Title: Identifying false positive variants using a significance model Dec. 16, 2025
-
Patent Title: Systems and methods for tumor fraction estimation from small variants Dec. 16, 2025
-
Patent Title: Methods for analyzing viral nucleic acid Nov. 04, 2025
-
Patent Title: Methylation markers and targeted methylation probe panel Oct. 07, 2025
-
Patent Title: Methylation markers and targeted methylation probe panel Sep. 09, 2025
-
Patent Title: Enrichment of short nucleic acid fragments in sequencing library preparation Aug. 12, 2025
-
Patent Title: Convolutional neural network systems and methods for data classification Aug. 05, 2025
-
Patent Title: Methods of preparing dual-indexed dna libraries for bisulfite conversion sequencing Apr. 01, 2025
-
Patent Title: Detecting cross-contamination in sequencing data Feb. 25, 2025
-
Patent Title: Systems and methods for using a convolutional neural network to detect contamination Feb. 25, 2025
-
Patent Title: Source of origin deconvolution based on methylation fragments in cell-free dna samples Feb. 25, 2025
-
Patent Title: Systems and methods for classifying patients with respect to multiple cancer classes Jan. 07, 2025
-
Patent Title: Base coverage normalization and use thereof in detecting copy number variation Sep. 24, 2024
-
Patent Title: Dynamically selecting sequencing subregions for cancer classification Aug. 27, 2024
-
Patent Title: Methods and systems for screening for conditions Jul. 30, 2024
-
Patent Title: Anomalous fragment detection and classification Jul. 02, 2024
-
Patent Title: Methods of preparing and analyzing cell-free nucleic acid sequencing libraries Jul. 02, 2024
-
Patent Title: Methylation markers and targeted methylation probe panel Jul. 02, 2024
-
Patent Title: Detecting cross-contamination in sequencing data using regression techniques Jun. 11, 2024
-
Patent Title: Models for targeted sequencing Apr. 16, 2024
-
Patent Title: Systems and methods for enriching for cancer-derived fragments using fragment size Mar. 12, 2024
-
Patent Title: Methods for managing sequencing pileups Feb. 27, 2024
-
Patent Title: Tissue-specific methylation marker Jan. 30, 2024
-
Patent Title: Systems and methods for determining whether a subject has a cancer condition using transfer learning Jan. 09, 2024
-
Patent Title: Enrichment of short nucleic acid fragments in sequencing library preparation Dec. 26, 2023
-
Patent Title: Methylation markers and targeted methylation probe panel Oct. 24, 2023
-
Patent Title: Convolutional neural network systems and methods for data classification Oct. 10, 2023
-
Patent Title: Systems and methods for automated classification of a document Oct. 10, 2023
-
Patent Title: Methylation-based false positive duplicate marking reduction Oct. 03, 2023
-
Patent Title: Methods and systems for analyzing nucleic acid sequences using mappability analysis and de novo sequence assembly Aug. 15, 2023
-
Patent Title: Methylation markers and targeted methylation probe panel Aug. 15, 2023
-
Patent Title: Methylation markers and targeted methylation probe panel Jun. 27, 2023
-
Patent Title: Needle-based devices and methods for in vivo diagnostics of disease conditions Jun. 20, 2023
-
Patent Title: Enrichment of mutated cell free nucleic acids for cancer detection Apr. 11, 2023
-
Patent Title: Methods of analyzing nucleic acid fragments Mar. 14, 2023
-
Patent Title: Library preparation and use thereof for sequencing based error correction and/or variant identification Feb. 21, 2023
-
Patent Title: Systems and methods for classifying patients with respect to multiple cancer classes Feb. 14, 2023
-
Patent Title: Methods of preparing dual-indexed dna libraries for bisulfite conversion sequencing Jan. 31, 2023
-
Patent Title: Methods for detecting disease using analysis of rna Nov. 29, 2022
-
Patent Title: Convolutional neural network systems and methods for data classification Oct. 25, 2022
-
Patent Title: Alignment free filtering for identifying fusions Oct. 18, 2022
-
Patent Title: Nucleic acid rearrangement and integration analysis Sep. 20, 2022
-
Patent Title: Methods for enriching for duplex reads in sequencing and error correction Aug. 16, 2022
-
Patent Title: Methylation markers and targeted methylation probe panel Aug. 09, 2022
-
Patent Title: Enhanced ligation in sequencing library preparation Mar. 15, 2022
Federal grants, loans, and purchases
Estimated quarterly amount awarded to GRAL from public contracts
Recent insights relating to GRAL
Recent picks made for GRAL stock on CNBC
ETFs with the largest estimated holdings in GRAL
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $GRAL stock a Buy, Sell, or Hold?
- What is the price target for $GRAL stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $GRAL stock?
- Who owns the most shares of $GRAL stock?
- What funds own $GRAL stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view GRAL Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
- Address Menlo Park, CA
- Market Cap 6.2 billion
- Employees 910
- Industrial Classification Services-Medical Laboratories
GRAIL, Inc. Common Stock (GRAL) Historical Stock Prices
Daily open, high, low, close, adjusted close and volume for GRAIL, Inc. Common Stock (GRAL).
Quiver Premium charts GRAL's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.
Upgrade to Premium| Date | Open | High | Low | Close | Adj. Close | Volume |
|---|
Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.
The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.
Explore the Quiver APIWe estimate that -- received a compensation of -- in --, making them the highest paid executive at GRAL, per a recent SEC DEF 14A filing.
|
Name
|
Role
|
Salary
|
Bonus
|
Stock/Option Awards
|
Total Compensation
|
|---|